Signum Surgical
A new technology for patients with anal fistula. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
€12—17m (Dealroom.co estimates Sep 2022.)
Company register number 584263
Galway County Galway (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€2.6m | Early VC | ||
€25.0k | Grant | ||
€2.3m | Grant | ||
$4.1m | Grant | ||
* | €2.9m | Late VC | |
Total Funding | €11.6m |
Recent News about Signum Surgical
EditMore about Signum Surgical
EditAfter a year of exploring the needs in gastrointestinal and colorectal care, Eoin Bambury and Moshe Zilversmit founded Signum Surgical in 2016 as a spin-out of the National University of Ireland BioInnovate programme. Signum Surgical is focused on developing innovative and effective solutions to treat colorectal diseases, starting with anal fistula – a painful and chronic colorectal condition that affects one in 5,000 people worldwide.
Requiring only an outpatient procedure, the company’s investigational BioHealx Technology is a minimally invasive, single-hand device developed to provide physicians ease of use, while substantially reducing surgeon training and procedure time, surgical trauma, and recovery time.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.